Cargando…
Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo
Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356390/ https://www.ncbi.nlm.nih.gov/pubmed/32545675 http://dx.doi.org/10.3390/molecules25122737 |
_version_ | 1783558488242257920 |
---|---|
author | Mapoung, Sariya Suzuki, Shugo Fuji, Satoshi Naiki-Ito, Aya Kato, Hiroyuki Yodkeeree, Supachai Sakorn, Natee Ovatlarnporn, Chitchamai Takahashi, Satoru Limtrakul (Dejkriengkraikul), Pornngarm |
author_facet | Mapoung, Sariya Suzuki, Shugo Fuji, Satoshi Naiki-Ito, Aya Kato, Hiroyuki Yodkeeree, Supachai Sakorn, Natee Ovatlarnporn, Chitchamai Takahashi, Satoru Limtrakul (Dejkriengkraikul), Pornngarm |
author_sort | Mapoung, Sariya |
collection | PubMed |
description | Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability. |
format | Online Article Text |
id | pubmed-7356390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73563902020-07-30 Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo Mapoung, Sariya Suzuki, Shugo Fuji, Satoshi Naiki-Ito, Aya Kato, Hiroyuki Yodkeeree, Supachai Sakorn, Natee Ovatlarnporn, Chitchamai Takahashi, Satoru Limtrakul (Dejkriengkraikul), Pornngarm Molecules Article Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability. MDPI 2020-06-12 /pmc/articles/PMC7356390/ /pubmed/32545675 http://dx.doi.org/10.3390/molecules25122737 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mapoung, Sariya Suzuki, Shugo Fuji, Satoshi Naiki-Ito, Aya Kato, Hiroyuki Yodkeeree, Supachai Sakorn, Natee Ovatlarnporn, Chitchamai Takahashi, Satoru Limtrakul (Dejkriengkraikul), Pornngarm Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo |
title | Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo |
title_full | Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo |
title_fullStr | Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo |
title_full_unstemmed | Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo |
title_short | Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo |
title_sort | dehydrozingerone, a curcumin analog, as a potential anti-prostate cancer inhibitor in vitro and in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356390/ https://www.ncbi.nlm.nih.gov/pubmed/32545675 http://dx.doi.org/10.3390/molecules25122737 |
work_keys_str_mv | AT mapoungsariya dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT suzukishugo dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT fujisatoshi dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT naikiitoaya dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT katohiroyuki dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT yodkeereesupachai dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT sakornnatee dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT ovatlarnpornchitchamai dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT takahashisatoru dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo AT limtrakuldejkriengkraikulpornngarm dehydrozingeroneacurcuminanalogasapotentialantiprostatecancerinhibitorinvitroandinvivo |